PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

• ClinicalTrials.gov Identifier: NCT04493619
• Recruitment Status: Terminated
• First Posted: July 30, 2020
• Last Update Posted: October 5, 2022
• Sponsor: Opna-IO LLC
• Information provided by (Responsible Party): Opna-IO LLC

Study Description

Brief Summary:

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.

Condition or disease	Intervention/treatment	Phase
Gynecologic Neoplasms; Epithelial Ovarian Cancer	Drug: PLX2853; Drug: Carboplatin	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 37 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
• Actual Study Start Date: August 11, 2020
• Actual Primary Completion Date: April 25, 2022
• Actual Study Completion Date: April 25, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: PLX2853 Phase 2a Monotherapy; Up to 26 evaluable subjects with ARID1A mutation-positive advanced gynecological malignancies will be enrolled.	Drug: PLX2853; PLX2853 tablets
Experimental: PLX2853 + Carboplatin Phase 1b/2a Combination Therapy; Phase 1b (PLX2853 + carboplatin combination): Up to 15 evaluable subjects with platinum-resistant EOC will be enrolled. Phase 2a (PLX2853 + carboplatin combination): Up to 26 evaluable subjects with platinum-resistant EOC will be enrolled.	Drug: PLX2853; PLX2853 tablets; Drug: Carboplatin; Carboplatin IV injection, 5 mg•min/mL

Outcome Measures

Primary Outcome Measures :

1. Phase 2a (PLX2853 monotherapy): overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [ Time Frame: From 8 weeks of treatment for only PLX2853 (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months. ]
2. Phase 1b (PLX2853 + carboplatin combination): establish the MTD/RP2D for the combination of PLX2853 and carboplatin [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
3. Phase 2a (PLX2853 + carboplatin combination): ORR as measured by RECIST v1.1 [ Time Frame: From 8 weeks of treatment with PLX2853 and Carboplatin (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months. ]

Secondary Outcome Measures :

1. Incidence of TEAEs that are related to treatment (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
2. Incidence of TEAEs that result in dose interruption, reduction or discontinuation (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
3. Incidence of treatment-emergent ECG abnormalities (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
4. Incidence of treatment-emergent laboratory abnormalities (both arms) [ Time Frame: From time of first dose of PLX2853 and Carboplatin until 30 days of end of treatment. ]
5. Duration Of Response (DOR) (both arms) [ Time Frame: From 8 weeks of treatment (Cycle 3 Day 1; 28 days per cycle) until completion of long term follow-up, an average of 6 months. ]
   DOR will be calculated for each subject with a response as the number of days from the date of first response (PR or CR confirmed at least 28 days later) to the date of the first documented disease progression or date of death from any cause, whichever occurs first.
6. Disease control rate (DCR) (both arms) [ Time Frame: From time of first dose until end of treatment, an average of 6 months. ]
   DCR will be calculated as the percentage of subjects with confirmed complete response (CR), Partial Response (PR), or Stable Disease (SD).
7. Progression-free survival (PFS) (both arms) [ Time Frame: From time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 24 months. ]
   Progression-free survival (PFS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment (Cycle 1 Day 1) to the date of the first documented disease progression or date of death from any cause, whichever occurs first.
8. Overall survival (OS) (both arms) [ Time Frame: From time of first dose until completion of long term follow-up, approximately 24 months. ]
   Overall survival (OS) will be calculated for each subject as the number of days from the first day of PLX2853 treatment (Cycle 1 Day 1) to the date of death from any cause.
9. PLX2853 PK parameter AUC0-last (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
   AUC from time zero to time of last observed concentration hours postdose (AUC0-last).
10. PLX2853 PK parameter AUC0-24 (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    AUC from time zero extrapolated to 24 hours (AUC0-24)
11. PLX2853 PK parameter AUC0-∞ (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    AUC from time zero extrapolated to infinite time (AUC0-∞)
12. PLX2853 PK parameter Cmax (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    Maximum observed concentration
13. PLX2853 PK parameter Tmax (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    Time to maximum observed concentration
14. PLX2853 PK parameter T1/2 (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    terminal elimination half-life (T1/2)
15. PLX2853 PK parameter accumulation ratio at steady state (both arms) [ Time Frame: From time of first dose until 30 days from end of treatment. ]
    accumulation ratio at steady state

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age ≥18 years at the time of signing informed consent

2. Histologically or cytologically confirmed diagnosis of 1 of the following, and must have measurable disease per RECIST v1.1:

   • Phase 2a (PLX2853 monotherapy): Any advanced gynecological malignancy (cervical, vaginal, vulvar, uterine, ovarian, fallopian tube, or primary peritoneal) with a known ARID1A mutation, that is intolerant to or refractory to all standard therapy known to confer clinical benefit.
   • Phase 1b and Phase 2a (PLX2853 + carboplatin combination):

   Platinum-resistant EOC (including fallopian tube or primary peritoneal cancer).

3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1
4. Adequate organ function as demonstrated by laboratory values.
5. Women of child bearing potential (defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal) must have a negative serum pregnancy test within 7 days prior to taking the first dose of study drug and, if sexually active, must agree to use a highly effective method of contraception (a contraception method with a failure rate <1% per year) and 1 additional barrier method from the time of the negative pregnancy test to 90 days after the last dose of study drug. Women of non-child bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
6. Except as specified above for organ function, all drug-related toxicity from previous cancer therapy must be resolved (to Grade ≤1 or baseline per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [NCI CTCAE v5.0]) prior to study treatment administration (Grade 2: alopecia, hot flashes, decreased libido, or neuropathy is allowed).
7. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements

Exclusion Criteria:

1. Prior exposure to a bromodomain inhibitor
2. Ongoing systemic infection requiring treatment with antibiotic, antiviral, or antifungal treatment
3. Autoimmune hemolytic anemia or autoimmune thrombocytopenia
4. Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
5. Red blood cell or platelet transfusion within 14 days of Screening blood draw
6. Known or suspected allergy to the investigational agent or any agent given in association with this study
7. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 μg (NIH-ODS 2020).
8. Use of strong inhibitors and inducers of CYP3A4 and 2C8
9. Clinically significant cardiac disease
10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption
11. Non-healing wound, ulcer, or bone fracture
12. Infection with HIV-1 or HIV-2. Exception: subjects with well-controlled HIV (e.g., CD4 >350/mm3 and undetectable viral load) are eligible.
13. Current active liver disease from any cause, including hepatitis A (hepatitis A virus immunoglobulin M positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid).

14. Active known second malignancy with the exception of any of the following:

    • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer
    • Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years
    • Any other cancer from which the subject has been disease-free for ≥3 years
15. Major surgery or significant traumatic injury within 28 days prior to Cycle 1 Day 1
16. Hospitalization for subacute bowel obstruction within 28 days prior to Cycle 1 Day 1

17. Receipt of anti-cancer therapy prior to Cycle 1 Day 1:

    • Chemotherapy, radiation therapy, or small molecule anti-cancer therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1
    • Immune therapy or other biologic therapy (e.g., monoclonal antibodies, antibody-drug conjugates) for the treatment of cancer within 21 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1 Subjects can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 28 days prior to treatment with study drug.
18. Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed).
19. Subjects who are pregnant or breast-feeding
20. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol or would interfere with the study endpoints or the subject's ability to participate.

Contacts and Locations

Locations

United States, Illinois

The University of Chicago Medical Center

Chicago, Illinois, United States, 05841

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

United States, New York

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, Oklahoma

University of Oklahoma - Stephenson Cancer Center

Oklahoma City, Oklahoma, United States, 73104

United States, Tennessee

Tennessee Oncology / Sarah Cannon

Nashville, Tennessee, United States, 37203

United States, Virginia

University of Virginia Health Systems

Charlottesville, Virginia, United States, 22908

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States, 22031

United States, Washington

University of Washington / Seattle Cancer Care Alliance

Seattle, Washington, United States, 98109

Canada, Ontario

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Sponsors and Collaborators

Opna-IO LLC

More Information

• Responsible Party: Opna-IO LLC
• ClinicalTrials.gov Identifier: NCT04493619
• Other Study ID Numbers: PLX124-03
• First Posted: July 30, 2020
• Last Update Posted: October 5, 2022
• Last Verified: October 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Opna-IO LLC:

PLX2853; Ovarian Cancer; ARID1A; Gynecological Malignancies; Carboplatin

Additional relevant MeSH terms:

Neoplasms; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Endocrine Gland Neoplasms; Neoplasms by Site; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carboplatin; Antineoplastic Agents